Eli Lilly won the race for the first oral GLP-1 pill. The commercial victory lap will have to wait.
The FDA approved orforglipron — branded Foundayo — on April 1, 2026, the first new molecular entity cleared under the agency's rare pediatric disease priority voucher program. The approval came 50 days after filing and 294 days ahead of its scheduled PDUFA date of January 20, 2027. It is the fastest NME approval since 2002, according to the FDA announcement.
That is real. But the market's reaction told a different story. Analysts at RBC Capital slashed 2026 consensus for Foundayo from roughly $4 billion to $1.6 billion in the weeks after approval, citing pricing headwinds and an increasingly crowded GLP-1 landscape, CNBC reported. Peak sales estimates still range from $18 billion to $40 billion by 2030 — but the path there just got harder.
The drug itself works. In the ATTAIN-1 trial, participants on the highest dose lost an average of 27.3 pounds, or 12.4% of body weight, compared with 2.2 pounds on placebo, Lilly said in its press release. The headline number is smaller than Novo Nordisk's oral Wegovy, which posted 16.6% average weight loss in comparable studies — and a cross-trial comparison showed Foundayo had roughly 14 times higher odds of treatment discontinuation due to side effects than Wegovy, according to CNBC.
Foundayo's real advantage is not efficacy. It is convenience. As a small molecule pill, not a peptide requiring injection, it can be taken any time of day without food or water restrictions. Novo's Wegovy requires fasting. That difference matters for adherence and for the patients who have been waiting for an oral option.
The pricing is aggressive by pharma standards. At $149 per month for the lowest dose and $349 for the highest via LillyDirect, it undercuts Wegovy's list price significantly. Commercially insured patients can access it for as little as $25 per month with a savings card, Lilly said. Medicare Part D coverage starts at $50 per month from July 1. Whether that translates to broad access depends on how pharmacy benefit managers position it, and early signals suggest managed care organizations are already pushing back on reimbursement terms that would limit which patients can access it.
Lilly licensed orforglipron from Chugai Pharmaceutical in 2018 for $50 million upfront plus up to $390 million in milestones, GEN News reported — a modest bet that now sits at the center of one of the most competitive drug markets in history. Novo is not standing still. Its oral formulation advantage is eroding but not gone. And Amgen, Structure Therapeutics, and others are advancing next-generation oral GLP-1 candidates that could further reshape the landscape.
The approval is a genuine milestone. A daily oral GLP-1 pill that does not require injections or food restrictions addresses one of the biggest patient objections to this drug class. Whether that is enough to overcome the side effect profile, the managed care negotiations, and the pricing pressure from a competitor with a better clinical dataset is the story the next twelve months will answer.
